Week in Review: A new heart pump recall | Embracing the future | Opportunistic imaging | Aspartame linked to new risks

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.” 

James Min, MD, Cleerly's founder and CEO, changed careers to address what he saw as a major unmet need in cardiology.

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

These findings show that opportunistic imaging could go a long way toward making more patients aware of the cardiovascular risks they face—all without requiring additional scans to be performed. 

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Researchers used advanced AI to see if any FDA-approved medications could potentially reverse one of the mutations behind dilated cardiomyopathy. Risedronate, a popular osteoporosis medication, is the one candidate that got the job done.

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

Sanofi's Merilog is a new biosimilar substitute for Novo Nordisk’s NovoLog. It can be used to treat adult and pediatric patients with type 1 and type 2 diabetes.